Skip to main content
Erschienen in: BMC Cancer 1/2018

Open Access 01.12.2018 | Research article

LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain

verfasst von: Hao Huang, Tian-Tian Tong, Lee-Fong Yau, Cheng-Yu Chen, Jia-Ning Mi, Jing-Rong Wang, Zhi-Hong Jiang

Erschienen in: BMC Cancer | Ausgabe 1/2018

Abstract

Background

Resistance to chemotherapy drugs (e.g. taxol) has been a major obstacle in successful cancer treatment. In A549 human lung adenocarcinoma, acquired resistance to the first-line chemotherapy taxol has been a critical problem in clinics. Sphingolipid (SPL) controls various aspects of cell growth, survival, adhesion, and motility in cancer, and has been gradually regarded as a key factor in drug resistance. To better understand the taxol-resistant mechanism, a comprehensive sphingolipidomic approach was carried out to investigate the sphingolipid metabolism in taxol-resistant strain of A549 cell (A549T).

Methods

A549 and A549T cells were extracted according to the procedure with optimal condition for SPLs. Sphingolipidomic analysis was carried out by using an UHPLC coupled with quadrupole time-of-flight (Q-TOF) MS system for qualitative profiling and an UHPLC coupled with triple quadrupole (QQQ) MS system for quantitative analysis. The differentially expressed sphingolipids between taxol-sensitive and -resistant cells were explored by using multivariate analysis.

Results

Based on accurate mass and characteristic fragment ions, 114 SPLs, including 4 new species, were clearly identified. Under the multiple reaction monitoring (MRM) mode of QQQ MS, 75 SPLs were further quantified in both A549 and A549T. Multivariate analysis explored that the levels of 57 sphingolipids significantly altered in A549T comparing to those of A549 (p < 0.001 and VIP > 1), including 35 sphingomyelins (SMs), 14 ceramides (Cers), 3 hexosylceramides (HexCers), 4 lactosylceramides (LacCers) and 1 sphingosine. A significant decrease of SM and Cer levels and overall increase of HexCer and LacCer represent the major SPL metabolic characteristic in A549T.

Conclusions

This study investigated sphingolipid profiles in human lung adenocarcinoma cell lines, which is the most comprehensive sphingolipidomic analysis of A549 and A549T. To some extent, the mechanism of taxol-resistance could be attributed to the aberrant sphingolipid metabolism, “inhibition of the de novo synthesis pathway” and “activation of glycosphingolipid pathway” may play the dominant role for taxol-resistance in A549T. This study provides insights into the strategy for clinical diagnosis and treatment of taxol resistant lung cancer.
Abkürzungen
A549T
Taxol-resistant strain of A549 cell
C1P
Ceramide-1-phosphate
Cer
Ceramide
DHCer
Dihydroceramide
DHSM
Dihydrosphingomyelin
HexCer
Hexosylceramide
LacCer
Lactosylceramide
QC
Quality control
SM
Sphingomyelin
SPL
Sphingolipid

Background

Lung cancer has been the leading cause of cancer mortality, and adenocarcinoma is its most prevalent form [1]. Paclitaxel (taxol) is commonly used as part of combination chemotherapy for the treatment of non-small cell lung cancer including adenocarcinoma A549. However, resistance to natural product chemotherapy drugs still constitutes a huge problem of successful cancer treatment, and the efficiency of chemotherapy is weakened because of paclitaxel resistance [2]. Potential mechanisms have been reported including multidrug resistance, β-tubulin alterations, detoxifying of paclitaxel, and apoptosis related genetic changes [3]. Although the extensive efforts have been made for understanding the underlying mechanisms, they are still elusive.
It has been recognized that the dysregulated metabolic profile of cancer is linked to the chemoresistance [4]. Cancer cells reprogram their metabolism to satisfy the demands of malignant phenotype, which decrease drug-induced apoptosis, conferring therapeutic resistance [5]. Since cellular SPLs appear to play a significant role in relation to cancer, their dysregulated synthesis and metabolism in drug-resistant cancer cells have been systematically studied [6]. Most previous studies focus on the biological effect of a kind of specific SPL like Cer [7] and S1P [8] on A549 cancer cell line. The sphingolipid profiles for A549 have been preliminary explored by using MALDI-TOF-MS, only two Cers have been defined as markers out of all the 9 SPLs detected in A549 [9]. The whole sphingolipidome in either A549 or A549T remains largely unrevealed. Recently, a versatile sphingolipidomic approach for both qualitative and quantitative analysis of up to 10 subclasses of SPLs has been established in our group [10]. In this study, the integrated LC-MS approach was employed to investigate the taxol resistance mechanism of A549T from the viewpoint of sphingolipidomic.

Methods

Chemicals and materials

The LIPID MAPS internal standard cocktail (internal standards mixture II, 25 μM each of 9 compounds in ethanol, catalog LM-6005) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). It was composed of uncommon SPLs which include: 17-carbon chain length sphingoid base analogs C17-sphingosine [So (d17:1)], C17-sphinganine [Sa (d17:0)], C17-sphingosine-1-phosphate [S1P (d17:1)], C17-sphinganine-1-phosphate [Sa1P (d17:0)], the C12-fatty acid analogs of the more complex SPLs C12-Ceramide [Cer (d18:1/12:0)], C12-ceramide-1-phosphate [C1P (d18:1/12:0)], C12-sphingomyelin [SM (d18:1/12:0)], C12-glucosylceramide [GlcCer (d18:1/12:0)], and C12-lactosylceramide [LacCer (d18:1/12:0)].
Acetic acid (CH3COOH, MS grade), formic acid (HCOOH, MS grade), ammonium acetate (NH4OAc, ACS grade) and potassium hydroxide (KOH, ACS grade) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The HPLC grade chloroform (CHCl3), isopropanol (IPA), as well as methanol (MeOH) were purchased from Merck (Darmstadt, Germany). Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium, Fetal Bovine Serum (FBS), Penicillin-Streptomycin (PS) were obtained from Gibco, New Zealand. Sodium dodecyl sulfate (SDS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were acquired from Acros, USA. Ultrapure water (18.2 MΩ) was supplied with a Milli-Q system (Millipore, MA, USA).

Cell culture and SPLs extraction

A549 human lung adenocarcinoma cell line (Cat.No. KG007) and its taxol-resistant strain (A549T, Cat.No. KG124) were obtained from KeyGen Biotech Co., Ltd. (Nanjing, China). A549 was cultured in DMEM supplemented with 10% FBS and 1% PS in a humidified 5% CO2 atmosphere at 37 °C. A549T was cultured in RPMI 1640 medium supplemented with solution consisted of 10% FBS, 1% PS and 200 ng/mL taxol in a humidified 5% CO2 atmosphere at 37 °C. For lipid analysis, A549 and A549T cells were respectively seeded into 6-well plates at the density of 1.5 × 105 cells/well and incubated for 48 h. Lipids were extracted from the cells, when they were grown to 80% confluence. After rinsed twice by ice-cold PBS, the cells were scraped into a borosilicate glass tube, in which 0.5 mL of MeOH, 0.25 mL of CHCl3 and 10 μL of 2.5 μM internal standards cocktail were added. The extract procedure was carried out by incubation at 48 °C for 12 h after sonicated at ambient temperature for 30 s. After 75 μL of KOH in MeOH (1 M) was added, the mixture was placed into a shaking incubator at 37 °C for 2 h. Acetic acid was used to neutralize the mixture before the typical four-step extraction was carried out for the preparation of SPLs. Further details for extracting SPLs and sample preparation were the same as previously described [11]. MTT assay was employed to evaluate the sensitivity of A549 and A549T cells to taxol. The IC50s were 67.72 nM and 124.7 μM, respectively corresponding to A549 and A549T, showing almost 2000-fold difference in taxol sensitivity between these two cell lines.

LC-MS conditions

Sphingolipid analysis was performed by using our developed LC-MS method with minor optimization, just as described previously [10, 11]. Chromatographic separation was achieved by using an Agilent 1290 UHPLC system, and it was interfaced with an Agilent ultrahigh definition 6550 Q-TOF mass spectrometer and an Agilent 6460 triple-quadrupole mass spectrometer respectively for qualitative- and quantitative-analysis. The acquisition and data analysis were operated by using Agilent MassHunter Workstation Software.

Data analysis

Based on the Agilent Personal Compound Database and Library (PCDL) software and LIPID MAPS Lipidomics Gateway, a personal database has been established with the latest update of 32,622 SPLs until August 06 2016. The screening and identification of SPLs were carried out by searching against it.
In qualitative research, the sphingolipidomic approach was applied by analyzing QC samples equally pooled by A549 and A549T. In quantitative research, A549 cells (models, n = 10) and A549T cells (models, n = 10), as well as QC samples (n = 5), were analyzed in parallel. Multivariate statistical analysis, including principle component analysis (PCA) and partial least squares to latent structure-discriminant analysis (PLS-DA) methods, were performed to examine significant differences between A549 and A549T, using SIMCA-P+ software version 14.0 (Umetrics, Umea, Sweden). Variable Importance in the Project (VIP) value in PLS-DA model was used for selecting and identifying biomarkers. The altered SPL with a VIP value larger than 1.00 was considered as a biomarker.

Results

Comprehensive profiling of sphingolipids in A549 and A549T cells

QC samples were analyzed repeatedly to achieve comprehensive profiling of SPLs in A549 and A549T. In various subclasses of SPLs, the [M + H]+ ions exhibits highest intensities in positive ion mode. Totally 114 SPLs have been identified in the QC samples, among which Cer (d18:2/26:2), DHCer (d18:0/24:2), phytosphingosine (PTSo) t19:2, and PTSo t16:1 were new SPLs. Notably, 4 pairs of isobaric species (A1-A4 vs a1-a4) and 21 pairs of isomeric species (B1-B21 vs b1-b21) were clearly distinguished in this study. Respective qualitative test of A549 and A549T revealed that they share all the same species of SPLs. The full identification result was listed in Table 1.
Table 1
Identification and quantification of SPLs in A549/A549T cells by using UHPLC-Q-TOF and UHPLC-QQQ MS
Class
Name
[M + H]+ m/z
tR (min)
Molecular Formula
Measured Mass
Calculated Mass
Error (ppm)
MS/MS Fragments (m/z)
MRM transitions
SM
d18:1/26:0 [B1]
843.7314
18.483
C49 H99 N2 O6 P
842.7240
842.7241
−0.12
264.2674, 184.0730
843.7
184.1
d18:1/26:1
841.7096
17.136
C49 H97 N2 O6 P
840.7026
840.7084
−6.90
264.2682, 184.0739
841.7
184.1
d18:1/25:0 [B2]
829.7154
17.702
C48 H97 N2 O6 P
828.7080
828.7084
−0.48
264.2683, 184.0732
829.7
184.1
d18:1/25:1 [B3]
827.6993
16.288
C48 H95 N2 O6 P
826.6915
826.6928
−1.57
264.2698, 184.0722
827.7
184.1
d18:1/24:0 [B4]
815.6992
17.020
C47 H95 N2 O6 P
814.6925
814.6928
−0.37
264.2697, 184.0732
815.7
184.1
d18:1/24:1 [B5]
813.6841
15.507
C47 H93 N2 O6 P
812.6769
812.6771
−0.25
264.2685, 184.0739
813.7
184.1
d18:1/24:2
811.6680
14.958
C47 H91 N2 O6 P
810.6607
810.6615
−0.99
264.2688, 184.0732
811.7
184.1
d18:1/24:3 [B6]
809.6526
14.243
C47 H89 N2 O6 P
808.6459
808.6458
0.12
264.2627, 184.0725
809.7
184.1
d18:1/23:0 [B7]
801.6839
16.371
C46 H93 N2 O6 P
800.6769
800.6771
−0.25
264.2645, 184.0727
801.7
184.1
d18:1/23:1 [B8]
799.6683
15.241
C46 H91 N2 O6 P
798.6608
798.6615
−0.88
264.2654, 184.0721
799.7
184.1
d18:1/23:2
797.6520
14.326
C46 H89 N2 O6 P
796.6443
796.6458
−1.88
264.2398, 184.0727
797.7
184.1
d18:1/22:0 [B9]
787.6679
15.723
C45 H91 N2 O6 P
786.6608
786.6615
−0.89
264.2665, 184.0730
787.7
184.1
d18:1/22:1 [B10]
785.6524
14.642
C45 H89 N2 O6 P
784.6452
784.6458
−0.76
264.2606, 184.0730
785.7
184.1
d18:1/22:2
783.6362
13.728
C45 H87 N2 O6 P
782.6291
782.6302
−1.41
264.2636, 184.0727
783.6
184.1
d18:1/21:0
773.6528
15.108
C44 H89 N2 O6 P
772.6455
772.6458
−0.39
264.2651, 184.0721
773.7
184.1
d18:1/21:1 [B11]
771.6361
14.010
C44 H87 N2 O6 P
770.6286
770.6302
−2.08
264.2624, 184.0732
771.6
184.1
d18:1/20:0
759.6368
14.459
C43 H87 N2 O6 P
758.6295
758.6302
−0.92
264.2658, 184.0730
759.6
184.1
d18:1/20:1 [B12]
757.6201
13.428
C43 H85 N2 O6 P
756.6128
756.6145
−2.25
264.2653, 184.0735
757.6
184.1
d18:1/19:0
745.6207
13.811
C42 H85 N2 O6 P
744.6134
744.6145
−1.48
264.2677, 184.0725
745.6
184.1
d18:1/18:0
731.6054
13.195
C41 H83 N2 O6 P
730.5982
730.5989
−0.96
264.2665, 184.0727
731.6
184.1
d18:1/18:1 [B13]
729.5869
12.081
C41 H81 N2 O6 P
728.5786
728.5832
−8.23
264.2659, 184.0732
729.6
184.1
d18:1/17:0
717.5896
12.613
C40 H81 N2 O6 P
716.5824
716.5832
−1.12
264.2677, 184.0726
717.6
184.1
d18:1/16:0
703.5737
12.081
C39 H79 N2 O6 P
702.5666
702.5676
−1.42
264.2680, 184.0748
703.6
184.1
d18:1/16:1 [B14]
701.5583
11.366
C39 H77 N2 O6 P
700.5511
700.5519
−1.14
264.2685, 184.0730
701.6
184.1
d18:1/15:0
689.5585
11.616
C38 H77 N2 O6 P
688.5512
688.5519
−1.02
264.2627, 184.0726
689.6
184.1
d18:1/15:1 [B15]
687.5420
10.752
C38 H75 N2 O6 P
686.5352
686.5363
−1.60
264.2629, 184.0720
687.5
184.1
d18:1/14:0
675.5427
11.117
C37 H75 N2 O6 P
674.5355
674.5363
−1.19
264.2686, 184.0734
675.5
184.1
d18:2/25:0 [b3]
827.6988
16.504
C48 H95 N2 O6 P
826.6896
826.6928
−3.87
262.2524, 184.0729
  
d18:2/24:0 [b5]
813.6763
15.873
C47 H93 N2 O6 P
812.6693
812.6771
−9.60
262.2542, 184.0726
  
d18:2/24:2 [b6]
809.6503
15.723
C47 H89 N2 O6 P
808.6457
808.6458
−0.12
262.2554, 184.0731
  
d18:2/24:3
807.6343
14.659
C47 H87 N2 O6 P
806.6272
806.6302
−3.71
184.0725
  
d18:2/23:0 [b8]
799.6684
15.474
C46 H91 N2 O6 P
798.6606
798.6615
−1.13
184.0732
799.7
184.1
d18:2/22:0 [b10]
785.6523
14.808
C45 H89 N2 O6 P
784.6451
784.6458
−0.89
262.2440, 184.0732
785.7
184.1
d18:2/21:0 [b11]
771.6357
14.193
C44 H87 N2 O6 P
770.6272
770.6302
−3.89
184.0722
  
d18:2/20:0 [b12]
757.6200
13.545
C43 H85 N2 O6 P
756.6128
756.6145
−2.25
262.2451, 184.0725
757.6
184.1
d18:2/18:0 [b13]
729.5896
12.347
C41 H81 N2 O6 P
728.5822
728.5832
−1.37
262.2554, 184.0728
  
d18:2/16:0 [b14]
701.5582
11.382
C39 H77 N2 O6 P
700.5510
700.5519
−1.28
262.2504, 184.0728
  
d18:2/15:0 [b15]
687.5433
10.951
C38 H75 N2 O6 P
686.5355
686.5363
−1.16
262.2503, 184.0716
  
d18:1/12:0 [IS-1]
647.5116
10.402
C35 H71 N2 O6 P
646.5042
646.5050
−1.24
264.2699, 184.0732
647.5
184.1
DHSM
d18:0/26:0
845.7455
19.182
C49 H101 N2 O6 P
844.7382
844.7397
−1.78
266.2711, 184.0730
  
d18:0/26:1 [b1]
843.7271
17.702
C49 H99 N2 O6 P
842.7202
842.7241
−4.63
266.2787, 184.0727
  
d18:0/25:0
831.7297
18.317
C48 H99 N2 O6 P
830.7224
830.7241
−2.05
184.0731
  
d18:0/25:1 [b2]
829.7149
17.469
C48 H97 N2 O6 P
828.7071
828.7084
−1.57
266.2729, 184.0729
  
d18:0/24:0
817.7151
17.585
C47 H97 N2 O6 P
816.7081
816.7084
−0.37
266.2696, 184.0732
817.7
184.1
d18:0/24:1 [b4]
815.6992
16.405
C47 H95 N2 O6 P
814.6931
814.6928
0.37
266.2767, 184.0732
  
d18:0/23:0
803.6995
16.937
C46 H95 N2 O6 P
802.6921
802.6928
−0.87
184.0725
803.7
184.1
d18:0/23:1 [b7]
801.6842
15.756
C46 H93 N2 O6 P
800.6767
800.6771
−0.50
184.0728
801.7
184.1
d18:0/22:0
789.6838
16.272
C45 H93 N2 O6 P
788.6771
788.6771
0.00
184.0129
789.7
184.1
d18:0/22:1 [b9]
787.6684
15.141
C45 H91 N2 O6 P
786.6612
786.6615
−0.38
184.0731
  
d18:0/21:0
775.6672
15.640
C44 H91 N2 O6 P
774.6598
774.6615
−2.19
184.0728
  
d18:0/20:0
761.6528
14.958
C43 H89 N2 O6 P
760.6452
760.6458
−0.79
184.0728
761.7
184.1
d18:0/19:0
747.6355
14.326
C42 H87 N2 O6 P
746.6312
746.6302
1.34
184.0728
747.6
184.1
d18:0/18:0
733.6210
13.694
C41 H85 N2 O6 P
732.6140
732.6145
−0.68
184.0730
733.6
184.1
d18:0/17:0
719.6056
13.096
C40 H83 N2 O6 P
718.5982
718.5989
−0.97
266.2542, 184.0730
719.6
184.1
d18:0/16:0
705.5896
12.514
C39 H81 N2 O6 P
704.5823
704.5832
−1.28
184.0739
705.6
184.1
d18:0/15:0
691.5737
11.982
C38 H79 N2 O6 P
690.5666
690.5676
−1.45
184.0729
691.6
184.1
d18:0/14:0
677.5586
11.466
C37 H77 N2 O6 P
676.5512
676.5519
−1.03
266.2797, 184.0729
677.6
184.1
Cer
d18:1/26:0
678.6745
20.495
C44 H87 N O3
677.6679
677.6686
−1.03
264.2681
  
d18:1/25:0
664.6584
19.481
C43 H85 N O3
663.6526
663.6529
−0.45
264.2654
  
d18:1/24:0 [B16]
650.6436
18.566
C42 H83 N O3
649.6365
649.6373
−1.23
264.2652
650.6
264.3
d18:1/24:1 [B17]
648.6280
17.219
C42 H81 N O3
647.6208
647.6216
−1.24
264.2681
648.6
264.3
d18:1/23:0
636.6272
17.070
C41 H81 N O3
635.6251
635.6216
5.51
264.2681
636.6
264.3
d18:1/23:1
634.6120
16.588
C41 H79 N O3
633.6045
633.6060
−2.37
264.2685
634.6
264.3
d18:1/22:0 [B18]
622.6124
17.086
C40 H79 N O3
621.6050
621.6060
−1.61
264.2680
622.6
264.3
d18:1/22:1 [B19]
620.5964
15.956
C40 H77 N O3
619.5891
619.5903
−1.94
264.2681
620.6
264.3
d18:1/20:0
594.5805
15.706
C38 H75 N O3
593.5732
593.5747
−2.53
264.2686
594.6
264.3
d18:1/18:0
566.5497
14.376
C36 H71 N O3
565.5423
565.5434
−1.95
264.2673
566.5
264.3
d18:1/18:1
564.5302
13.478
C36 H69 N O3
563.5233
563.5278
0.53
264.2669
563.5
264.3
d18:1/17:0
574.5155
13.744
C35 H69 N O3
551.5259
551.5277
−3.26
264.2670
  
d18:1/16:0
538.5186
13.112
C34 H67 N O3
537.5114
537.5121
−1.30
264.2683
538.5
264.3
d18:1/16:1 [B20]
536.5028
12.298
C34 H65 N O3
535.4952
535.4964
−2.24
264.2681
536.5
264.3
d18:1/15:0
524.5026
12.564
C33 H65 N O3
523.4955
523.4964
−1.72
264.2659
524.5
264.3
d18:1/14:0
510.4868
11.982
C32 H63 N O3
509.4793
509.4808
−2.94
264.2696
  
d18:2/26:2
672.6258
18.566
C44 H81 N O3
671.6185
671.6216
−4.62
262.2530
672.6
262.3
d18:2/24:1
646.6121
16.288
C42 H79 N O3
645.6047
645.6060
−2.01
262.2528
646.6
262.3
d18:2/22:0 [b19]
620.5960
16.139
C40 H77 N O3
619.5886
619.5903
−2.74
262.2528
620.6
262.3
d18:2/16:0 [b20]
536.5029
12.554
C34 H65 N O3
535.4953
535.4964
−2.05
262.2532
  
d18:1/12:0 [IS-2]
482.4556
11.034
C30 H59 N O3
481.4479
481.4495
−3.32
264.2678
482.5
264.3
DHCer
d18:0/24:0
652.6587
19.198
C42 H85 N O 3
651.6513
651.6529
−2.46
266.2853
652.7
266.3
d18:0/24:1 [b16]
650.6434
17.735
C42 H83 N O3
649.6361
649.6373
−1.85
266.2837
  
d18:0/24:2 [b17]
648.6281
17.502
C42 H81 N O3
647.6209
647.6216
−1.08
266.2826
  
d18:0/22:0
624.6277
17.569
C40 H81 N O3
623.6202
623.6216
−1.12
266.2859
  
d18:0/22:1 [b18]
622.6111
16.438
C40 H79 N O3
621.6036
621.6060
−3.86
266.2779
  
d18:0/20:0
596.5956
16.222
C38 H77 N O3
595.5878
595.5903
−4.20
266.2811
  
d18:0/18:0
568.5650
14.858
C36 H73 N O3
567.5578
567.5590
−2.11
266.2844
  
d18:0/16:0
540.5343
13.561
C34 H69 N O3
539.5272
539.5277
−0.93
266.2822
  
PTCer
t18:0/14:0
528.4981
11.333
C32 H65 N O4
527.4908
527.4914
−1.14
514.4823, 264.2687
  
HexCer
d18:1/26:0
840.7273
18.467
C50 H97 N O8
839.7189
839.7214
− 2.98
264.2685
840.7
264.3
d18:1/24:0
812.6974
17.020
C48 H93 N O8
811.6893
811.6901
−0.99
264.2685
812.7
264.3
d18:1/24:1
810.6809
16.654
C48 H91 N O8
809.6732
809.6745
−1.61
264.2677
810.7
264.3
d18:1/23:0
798.6804
16.388
C47 H91 N O8
797.6725
797.6745
−2.51
264.2676
798.7
264.3
d18:1/22:0
784.6656
15.740
C46 H89 N O8
783.6579
783.6588
−1.15
264.2689
784.7
264.3
d18:1/16:0
700.5717
12.115
C40 H77 N O8
699.5621
699.5649
−4.00
264.2689
700.6
264.3
d18:1/12:0 [IS-3]
644.5101
10.435
C36 H69 N O8
643.5007
643.5023
−2.49
264.2684
644.5
264.3
LacCer
d18:1/24:0
974.7508
16.388
C54 H103 N O13
973.7432
973.7429
0.31
264.2672
974.7
264.3
d18:1/24:1
972.7329
15.257
C54 H101 N O13
971.7253
971.7273
−2.06
264.2650
972.7
264.3
d18:1/22:0
946.7190
15.124
C52 H99 N O13
945.7112
945.7116
−0.42
264.2679
946.7
264.3
d18:1/20:0
918.6866
13.894
C50 H95 N O13
917.6780
917.6803
−2.51
264.2688
  
d18:1/18:0
890.6552
12.713
C48 H91 N O13
889.6469
889.6490
−2.36
264.2696
890.7
264.3
d18:1/16:0
862.6250
11.682
C46 H87 N O13
861.6175
861.6177
−0.23
264.2687
862.6
264.3
d18:1/12:0 [IS-4]
806.5623
10.219
C42 H79 N O13
805.5550
805.5551
−0.13
264.2683
806.7
264.3
Sa
d19:0 [A1]
316.3202
6.532
C19 H41 N O2
315.3135
315.3137
−0.63
298.3106, 272.2906
274.3
256.3
d18:0 [B21] [A2]
302.3050
6.993
C18 H39 N O2
301.2972
301.2981
−2.98
284.2921
302.3
284.3
d16:0
274.2739
4.881
C16 H35 N O2
273.2666
273.2668
0.73
256.2627
274.3
256.3
PTSa
t17:0
304.2874
5.468
C17 H37 N O3
303.2782
303.2773
2.68
286.2751
  
d17:0 [A3] [IS-5]
288.2901
6.632
C17 H37 N O2
287.2829
287.2824
1.65
270.2794
288.3
270.3
So
d19:1
314.3051
10.668
C19 H39 N O2
313.2978
313.2981
−0.96
296.3320
  
d18:1
300.2896
6.760
C18 H37 N O2
299.2822
299.2824
−0.67
282.2787, 264.2689
300.3
282.3
d17:1 [A4]
286.2737
6.444
C17 H35 N O2
285.2659
285.2668
−3.15
270.2783
  
d16:1
272.2582
5.264
C16 H33 N O2
271.2505
271.2511
−2.36
254.2833
272.3
254.3
d15:1
258.2425
6.711
C15 H31 N O2
257.2347
257.2355
−3.11
240.2319
  
d15:2
256.2270
5.064
C15 H29 N O2
255.2192
255.2198
−2.35
238.2214
  
PTSo
t19:1
330.3003
8.041
C19 H39 N O3
329.2954
329.2930
7.29
312.3278
  
t19:2
328.2846
6.245
C19 H37 N O3
327.2771
327.2773
−0.61
310.2996
  
t18:1 [a1]
316.2850
6.874
C18 H37 N O3
315.2739
315.2773
10.8
298.2739, 280.2632, 262.2522
316.3
298.3
t17:1 [a2]
302.2687
7.176
C17 H35 N O3
301.2618
301.2617
0.33
284.2921, 266.2838
302.3
284.3
t16:1 [a3]
288.2537
5.663
C16 H33 N O3
287.2459
287.2460
−0.35
270.2786
  
d17:1 [a4] [IS-6]
286.3106
6.558
C18 H39 N O
285.3034
285.3032
0.74
268.2643
286.3
268.3
SBA
Enigmol [b21] [A2]
302.3052
5.081
C18 H39 N O2
301.2974
301.2981
−2.32
284.2930, 266.2090
  
SBA
Xestoaminol C
230.2477
5.131
C14 H31 N O
229.2404
229.2406
−0.87
212.2355
  
C1P
d18:1/12:0 [IS-7]
562.4223
10.006
C30 H60 N O6 P
561.4149
561.4158
−1.72
264.2688
562.5
264.3
Sa1P
d17:0 [IS-8]
368.2574
6.774
C17 H38 N O5 P
367.2504
367.2488
4.57
 
368.3
270.3
So1P
d17:1 [IS-9]
366.2406
6.558
C17 H36 N O5 P
365.2331
365.2331
0.03
250.2510
366.2
250.3
The sphingolipids are classified according to “lipid classification system” (http://​www.​lipidmaps.​org/​)
SM sphingomyelin, DHSM dihydrosphingomyelin, Cer Ceramide, DHCer dihydroceramide, PTCer phytoceramides, HexCer hexosylceramide, LacCer lactosylceramide, Sa sphinganine, PTSa phytosphinganine, So sphingosine, PTSo phytosphingosine, SBA sphingoid base analog, C1P ceramide-1-phosphate, Sa1P sphinganine-1-phosphate, So1P sphingosine-1-phosphate
[A1-A4 vs a1-a4] 4 pairs of isomeric sphingolipids; [B1-B21 vs b1-b21], 21 pairs of isomeric sphingolipids; [IS], internal standard
Interpretation of high resolution MS and MS/MS spectra of each identified ion, as well as searching against the latest database, allowed for the accurate identification of SPLs. For instance, isobaric lipids could be differentiated by the high-resolution mass spectrometry-based approaches. Two peaks yield m/z 316 ions, with accurate mass acquired by Q-TOF, m/z 316.3202 at 6.532 min and m/z 316.2850 at 6.874 min correspond to [C19H41NO2 + H]+ and [C18H37NO3 + H]+ respectively, facilitating assignment of sphinganine (Sa) d19:0 and phytosphingosine (PTSo) t18:1. Further fragmentation in MS/MS confirmed the identification, a consecutive loss of 3 hydroxy groups can be observed in the latter case, which is the characteristic cleavage of PTSo (Fig. 1).
A more realistic interference in the identification of SPLs is the isomeric species that have same number of atoms of each element, thus MS/MS fragment data with the assistance of optimized separation are essential for distinguishing the isomers. Take SM (d18:1/22:1) and SM (d18:2/22:0) as example, there are 2 peaks corresponding to m/z 785.65 in extracted ion chromatogram of TOF MS. In accurate MS/MS data acquired by Q-TOF, two characteristic fragments (264.3 & 262.3) respectively corresponding to the sphingoid base chain of SM (d18:1/22:1) and SM (d18:2/22:0) were observed (Fig. 2). The targeted ion pairs as well as complete chromatographic separation make the accurate MRM quantification of isomers possible.
Ceramides are prone to fragment into product ions corresponding to the sphingoid base backbone (e.g. m/z 262.25, 264.27, 266.28). In A549 QC samples, 29 Cers, including 20 dehydroceramides, 8 dihydroceramides (DHCers) and 1 phytoceramide (PTCer), were identified by comparing the MS information and retention time with those of SPLs in our previous study [10, 11]. Most Cers detected in the samples were with a d18:1 sphingoid backbone and the carbon number of N-acyl side chain varied from 14 to 26. A new dihydroceramide DHCer (d18:0/24:2), and Cer (d18:2/26:2), a dehydroceramide with high degree of unsaturation and long N-acyl chain, have been characterized for the first time to the best of our knowledge.
SM is the most multitudinous subclass of SPLs in A549 and A549T. Based on the exact mass in TOF MS and characteristic product ions obtained by Q-TOF MS/MS, a total of 56 SMs, including 38 dehydrosphingomyelins and 18 dihydrosphingomyelins (DHSMs), were unambiguously identified. All these SMs were characterized with a C18 sphingoid base chain, among which d18:1 type takes the largest proportion. In the N-acyl side chain, the number of carbon ranged between 14 and 26, with an unsaturation degree up to 5. Notably, all the DHSMs with 21 or less carbons in the N-acyl chain are fully saturated, while the others (with more than 21 carbons in the N-acyl chain) can be detected together with their corresponding de-hydrogen form. Three highly unsaturated SMs (total unsaturation degree no less than 4) including SM (d18:1/24:3), SM (d18:2/24:2) and SM (d18:2/24:3), have been detected in the QC sample of A549 & A549T cells.
Hexose-linked glycoceramide including galactosylceramide (GalCer) and glucosylceramide (GluCer) were represented as HexCer. All the 6 HexCers and 6 LacCers were found with d18:1 sphingoid base backbone. Only one HexCer with N-acyl chain in odd carbon number, HexCer (d18:1/23:0) was identified in A549. Notably, among all the HexCers and LacCers, only d18:1/24:1 species were identified as glycoceramides with unsaturated N-acyl fatty chain.
Seventeen sphingoid bases as well as the analogs were also successfully identified. The carbon number ranging from 14 to 19 and the degree of unsaturation falls between 0 and 2. Two PTSo with 3 hydroxyl groups, PTSo t19:2 and PTSo t16:1, have been discovered for the first time.

Quantitation of sphingolipids in A549 and A549T cells

MRM mode of UHPLC-QQQ MS could provide accurate and sensitive approach under a wide range for quantitative analysis of SPLs. As the accuracy of triple-quadruple is about 0.1 Da, the quantification of SPLs cannot be accurately achieved merely with a QQQ analyzer, especially when suffering the isotopic interferences. Every unsaturated SPL could be recognized as an isotope of another one with the same characteristic backbone but less degree of unsaturation. For instance, if the LC separation is incomplete, the content of Cer (d18:1/24:0) will be artificially high due to the interference of Cer (d18:1/24:1) (Fig. 3). In this study, based on UHPLC complete separation and Q-TOF comprehensive profiling, accurate quantification was accomplished by eliminating the isotopic interference. By using the UHPLC-QQQ MS method with the optimized MRM parameters, a total of 75 species out of 114 identified SPLs were quantified in A549 and A549T cells, respectively. The amounts of these SPLs were quantified by comparing with the foregoing mentioned ISs.
The quantitative results indicated that SMs account for the majority of all the SPLs in A549 and A549T, among which SMs with C16/C18/C22/C24 N-acyl side chain took the largest proportion of the total content. SMs with d18:1 sphingoid backbone are the most dominant species, which take 27 out of all the 41 quantified SMs (Fig. 4). For some SMs with high unsaturation degree or long N-acyl chain, the content is extremely low which cannot reach the limit of quantitation (LOQ). Figure 5 shows quantification data of 17 Cers. In general, the amounts of various Cers are significantly higher in A549 rather than those in A549T. Similar to SM, d18:1 Cers with C16/C18/C22/C24 N-acyl side chain showed relative high levels in both A549 and A549T, which take most proportion of Cer. LacCers and HexCers were only found with d18:1 sphingoid base backbone. All the 6 LacCers showed higher intensity in A549T than that in A549. But HexCer showed a species-dependent trend, HexCer d18:1/16:0, HexCer d18:1/22:0 and HexCer d18:1/23:0 increased in A549T, while HexCer d18:1/24:0, HexCer d18:1/24:1 and HexCer d18:1/26:0 decreased (Fig. 6). The overall content of sphingoid bases was similar in both cell types, Sa d16:0 was found with the highest intensity (Fig. 7). The relative abundance of each SPL varied greatly, but SPLs with N-acyl chain length of C16 and C24, respectively, are the most abundant species within each subclass.
PCA was used for the overview of SPL dataset and the spotting of outliers, and thereby pick out trends of grouping or separation. It was performed to visualize general clustering among A549, A549T and QC groups [R2X (cum) = 0.874, Q2 (cum) = 0.845; Fig. 8a]. Supervised PLS-DA was used to further study the differences between A549 and A549T and to select potential biomarkers. In PLS-DA, the result of model showed the performance statistics of R2X (cum) = 0.880, R2Y (cum) = 0.999 with an excellent prediction parameter Q2 (cum) = 0.998, and the score plot showed good visual separation between A549 and A549T groups as well (Fig. 8b). A total of 57 potential biomarkers were identified according to scattering-plot and the VIP value (Table 2), among which most of them are SM and Cers. SM (d18:0/18:0) showed the largest decline in A549T, the content in decreased from 17.0 to 0.10 pmol/(5 × 105cells), that markedly contributes to the classification.
Table 2
Quantification of SPLs (VIP > 1) in A549 and A549T
SPLs
Content (pmol/5*105 cells)
ChangeA549T vs A549
p value
VIP
A549 (n = 20)
A549T (n = 20)
SM (d18:2/20:0)
1.96 ± 0.16
0.53 ± 0.07
< 0.001
1.07408
SM (d18:1/26:1)
19.8 ± 1.22
0.34 ± 0.04
< 0.001
1.08696
SM (d18:1/26:0)
5.67 ± 0.31
0.20 ± 0.02
< 0.001
1.08775
SM (d18:1/25:1)
9.28 ± 0.43
0.45 ± 0.05
< 0.001
1.08860
SM (d18:1/25:0)
4.09 ± 0.23
0.42 ± 0.04
< 0.001
1.08699
SM (d18:1/24:3)
3.34 ± 0.26
0.47 ± 0.07
< 0.001
1.08120
SM (d18:1/24:2)
32.5 ± 1.55
8.99 ± 0.87
< 0.001
1.08501
SM (d18:1/24:1)
542 ± 23.8
37.9 ± 2.59
< 0.001
1.08879
SM (d18:1/24:0)
298 ± 13.0
41.5 ± 3.16
< 0.001
1.08829
SM (d18:1/23:2)
1.12 ± 0.11
0.25 ± 0.04
< 0.001
1.06488
SM (d18:1/23:1)
21.6 ± 1.08
2.58 ± 0.30
< 0.001
1.08745
SM (d18:1/23:0)
26.4 ± 1.26
6.57 ± 0.51
< 0.001
1.08618
SM (d18:1/22:2)
1.25 ± 0.12
0.15 ± 0.02
< 0.001
1.07067
SM (d18:1/22:1)
16.4 ± 0.81
2.07 ± 0.18
< 0.001
1.08760
SM (d18:1/22:0)
142 ± 6.17
26.9 ± 1.78
< 0.001
1.08783
SM (d18:1/21:1)
0.82 ± 0.07
0.15 ± 0.02
< 0.001
1.07308
SM (d18:1/21:0)
4.66 ± 0.25
1.39 ± 0.12
< 0.001
1.08216
SM (d18:1/20:1)
0.87 ± 0.13
0.06 ± 0.00
< 0.001
1.06102
SM (d18:1/20:0)
17.6 ± 0.86
3.08 ± 0.31
< 0.001
1.08689
SM (d18:1/19:0)
1.94 ± 0.20
0.21 ± 0.03
< 0.001
1.07588
SM (d18:1/18:1)
39.0 ± 1.99
8.13 ± 0.58
< 0.001
1.08637
SM (d18:1/18:0)
69.5 ± 2.72
9.07 ± 0.54
< 0.001
1.08896
SM (d18:1/17:0)
14.1 ± 0.72
4.76 ± 0.39
< 0.001
1.08307
SM (d18:1/16:0)
982 ± 38.5
629 ± 23.5
< 0.001
1.06108
SM (d18:1/14:0)
27.3 ± 1.04
17.2 ± 0.65
< 0.001
1.06732
SM (d18:0/24:0)
15.3 ± 0.78
0.11 ± 0.02
< 0.001
1.08843
SM (d18:0/23:0)
2.45 ± 0.15
0.02 ± 0.00
< 0.001
1.08694
SM (d18:0/22:0)
23.3 ± 1.05
0.23 ± 0.04
< 0.001
1.08900
SM (d18:0/20:0)
4.59 ± 0.24
0.08 ± 0.01
< 0.001
1.08808
SM (d18:0/19:0)
0.49 ± 0.07
0.01 ± 0.00
< 0.001
1.05519
SM (d18:0/18:0)
17.0 ± 0.55
0.10 ± 0.03
< 0.001
1.09013
SM (d18:0/17:0)
0.65 ± 0.07
0.06 ± 0.01
< 0.001
1.07030
SM (d18:0/16:0)
545 ± 28.7
12.3 ± 0.94
< 0.001
1.08809
SM (d18:0/15:0)
1.74 ± 0.16
0.10 ± 0.02
< 0.001
1.08041
SM (d18:0/14:0)
5.83 ± 0.40
0.28 ± 0.03
< 0.001
1.08565
Cer (d18:2/24:1)
1.01 ± 0.21
0.03 ± 0.01
< 0.001
1.04397
Cer (d18:1/24:1)
46.1 ± 5.83
3.60 ± 0.44
< 0.001
1.07110
Cer (d18:1/24:0)
42.0 ± 2.08
9.83 ± 0.41
< 0.001
1.08653
Cer (d18:1/23:1)
1.37 ± 0.22
0.06 ± 0.01
< 0.001
1.06057
Cer (d18:1/23:0)
2.54 ± 0.27
0.53 ± 0.09
< 0.001
1.06941
Cer (d18:1/22:1)
1.20 ± 0.27
0.04 ± 0.01
< 0.001
1.03542
Cer (d18:1/22:0)
14.4 ± 0.94
1.90 ± 0.39
< 0.001
1.08443
Cer (d18:1/20:0)
1.69 ± 0.33
0.07 ± 0.02
< 0.001
1.04721
Cer (d18:1/18:1)
20.1 ± 1.33
4.03 ± 0.49
< 0.001
1.08187
Cer (d18:1/18:0)
8.03 ± 0.72
0.26 ± 0.04
< 0.001
1.08142
Cer (d18:1/16:0)
52.0 ± 3.59
10.7 ± 0.98
< 0.001
1.08243
Cer (d18:1/15:0)
3.14 ± 0.46
1.34 ± 0.30
< 0.001
1.00100
Cer (d18:0/24:0)
1.44 ± 0.11
0.34 ± 0.04
< 0.001
1.07587
Cer (d18:0/16:0)
3.46 ± 0.25
0.07 ± 0.01
< 0.001
1.05883
HexCer (d18:1/26:0)
0.41 ± 0.10
0.04 ± 0.02
< 0.001
1.00780
HexCer (d18:1/24:1)
9.25 ± 0.97
0.02 ± 0.00
< 0.001
1.07959
HexCer (d18:1/16:0)
5.06 ± 0.89
21.6 ± 2.10
< 0.001
1.07118
LacCer (d18:1/24:1)
0.22 ± 0.05
19.9 ± 2.17
< 0.001
1.07014
LacCer (d18:1/24:0)
0.37 ± 0.03
56.4 ± 3.16
< 0.001
1.07766
LacCer (d18:1/22:0)
0.06 ± 0.01
21.6 ± 2.85
< 0.001
1.07258
LacCer (d18:1/16:0)
1.15 ± 0.55
115 ± 11.6
< 0.001
1.08013
So (t17:1)
2.21 ± 0.17
0.62 ± 0.08
< 0.001
1.07483

Discussion

Using the sphingolipidomic approach, we obtained the detailed sphingolipid profiles for human lung adenocarcinoma cell A549 and its taxol resistant strain A549T, and then performed quantification. We found A549 and A549T share all the same species of SPLs, among which SM (dehydrosphingomyelin and DHSM), Cer (dehydroceramide, DHCer and PTCer), HexCer, LacCer, and sphingoid base were identified as the major SPLs. In contrast to normal A549, decreasing levels of Cer and SM concomitant with increasing of glycosphingolipids represent the main SPL metabolic profile of A549T. Totally 35 SMs, 14 Cers, 3 HexCers, 4 LacCers, and 1 sphingosine are recognized as metabolic pathway related biomarkers.
Cer is the basic SPL structural unit which balances cell growth and death by inducing apoptosis [12], and its definite efficacy in promoting apoptosis in A549 cells has been well studied [7]. It is noteworthy that Cers can be classified into SM-hydrolyzed and de novo-synthesized. The former is well known as triggering apoptotic death signaling in many cell types, while the specific role of the latter one seems important to tumor survival [13]. In human ovarian carcinoma cell line CABA I, anti-cancer drugs including taxol have been reported to activate SMase to generate Cer, which acts as a second messenger in triggering apoptosis [14]. While in lung carcinoma cells, the tumor tissues produce large amounts of both dihydroceramide and ceramide through the de novo synthesis pathway, but not through SM hydrolysis [13]. More relevantly, treatment of A549 cells with gemcitabine was demonstrated to increase Cer levels via the activation of de novo synthesis [15]. In the case of study of A549T in this paper, both Cer and SM levels were much lower than their levels in taxol-sensitive A549 cells, which indicates that the decrease of Cer may not attribute to “activating the SM pathway” as our previous study in A2780T [11]. Furthermore, DHCer was decreasing accompanied with Cer, which revealed the mechanism of taxol-resistance in A549T could be explained as “inhibiting the de novo synthesis pathway”. (Fig. 9).
Both Cer and its catabolite sphingosine as negative regulators of cell proliferation could promote apoptosis, and the role of sphingosine as a messenger of apoptosis is of importance [16]. In small cell lung cancer (SCLC), multidrug-resistance-associated protein (MRP) contributes to the drug resistance, and pro-apoptotic SPLs (Cer and sphingosine) could further induce apoptosis overcome or bypass MRP-mediated drug resistance [17]. In non-small cell lung cancer (NSCLC) including A549, sphingosine kinase 2 (SphK2) is proposed to be the key regulator of sphingolipid signaling which may contribute to the apoptosis resistance [18]. Inhibition of SphK2 can enhance the apoptosis of NSCLC cells, and it will certainly result in an increase of the substrate sphingosine. In A549T, all sphingosines showed consistent trend of decrease comparing to A549. It’s known that sphingosine in mammalian cells is not synthesized de novo but it is generated from ceramides by ceramidases [19]. Thus, we can deduce that in A549T the concomitant decrease of sphingosine and Cer may be the result of activation of SphK2, which leads to the inhibition of apoptosis in taxol resistant strain.
Besides Cer and SM, glycosphingolipids including HexCers (GalCers & GluCers) and LacCers account for a large proportion of biomarkers in A549T. It has been observed that glucosylceramide synthase is up-regulated after drug intervention and suggests that glycolipids may be involved in chemotherapy resistance [2]. For decades, GluCer has been found to increase in the resistant cancer cells [20], suggesting that glycosylation plays an important role in evading Cer induced apoptosis. Glycosphingolipids have recently been reported as transactivating multidrug resistance 1/P-glycoprotein (MDR1) and multidrug resistance-associated protein 1 (MRP1) expression which further prevents accumulation of ceramide and stimulates drug efflux [21]. Specifically, GalCer and LacCer were characteristically increased in taxol-resistant human ovarian carcinoma-derived KF28TX cells [22]. Moreover, GalCer was demonstrated to be the apoptosis protector, and its upregulation was also thought to attenuate the Cer-mediated apoptotic signals [23]. Our findings revealed a significant overall increase of glycosphingolipids in A549T, among which all LacCers showed a consistent tendency of increase, while HexCers (including GalCer and GluCer) showed a species-dependent trend. It should be noted that GluCer could be converted into LacCer under the influence of lactosylceramide synthase. Therefore the decreased species of HexCer might be GluCer. For instance, the decrease of HexCer (d18:1/24:1) resulted in the concomitant increase of LacCer (d18:1/24:1).

Conclusions

Evidences suggest that tumor microenvironment including the sphingolipidome plays an important role in cancer drug resistance. So far to our knowledge, there is no sphingolipidomic study on taxol-resistant A549 human adenocarcinoma cell line. Based on the comprehensive identification and accurate quantification of SPLs, decreasing of Cer, SM and sphingosine concomitant with increasing of HexCer and LacCer have been characterized as the metabolic profile of A549T. It indicated that “inhibition of the de novo synthesis pathway” and “activation of glycosphingolipid pathway” played the dominant role for taxol-resistance, and the key enzymes related to the pathways may have been altered. These results provide evidence to unravel the mechanism of taxol resistance in A549T. The distinctive phenotype could facilitate clinical diagnosis of taxol-resistant adenocarcinoma and provide insights into targets for the development of new drug against taxol resistance.

Funding

This work was financially supported by Tertiary Education Services Office, Macau Special Administrative Region (GAES-17-001-SKL to Z.-H. Jiang); Macao Science and Technology Development Fund, Macau Special Administrative Region (015/2017/AFJ to Z.-H. Jiang and 023/2016/AFJ to J.-R Wang); and in part by Ph.D. start-up fund of Gannan Medical University (No.201304 granted to H. Huang). The funding bodies have no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets used and analyzed during the current study were available from the corresponding author(s) on reasonable request.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
2.
Zurück zum Zitat Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther. 2004;3(5):633–9.PubMed Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther. 2004;3(5):633–9.PubMed
3.
Zurück zum Zitat Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1–19.CrossRefPubMed Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1–19.CrossRefPubMed
4.
Zurück zum Zitat Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18(3):207–19.CrossRefPubMedPubMedCentral Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18(3):207–19.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Giussani P, Tringali C, Riboni L, Viani P, Venerando B. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int J Mol Sci. 2014;15(3):4356–92.CrossRefPubMedPubMedCentral Giussani P, Tringali C, Riboni L, Viani P, Venerando B. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int J Mol Sci. 2014;15(3):4356–92.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kurinna SM, Tsao CC, Nica AF, Jiffar T, Ruvolo PP. Ceramide promotes apoptosis in lung cancer-derived A549 cells by a mechanism involving c-Jun NH2-terminal kinase. Cancer Res. 2004;64(21):7852–6.CrossRefPubMed Kurinna SM, Tsao CC, Nica AF, Jiffar T, Ruvolo PP. Ceramide promotes apoptosis in lung cancer-derived A549 cells by a mechanism involving c-Jun NH2-terminal kinase. Cancer Res. 2004;64(21):7852–6.CrossRefPubMed
8.
Zurück zum Zitat Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, Evans JH, Freiberg J, Roddy P, Hannun YA, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem. 2004;279(12):11320–6.CrossRefPubMed Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, Evans JH, Freiberg J, Roddy P, Hannun YA, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem. 2004;279(12):11320–6.CrossRefPubMed
9.
Zurück zum Zitat Yu Y, Sun G, Liu G, Wang Y, Shao Z, Chen Z, Yang J. Effects of mycoplasma pneumoniae infection on sphingolipid metabolism in human lung carcinoma A549 cells. Microb Pathog. 2009;46(2):63–72.CrossRefPubMed Yu Y, Sun G, Liu G, Wang Y, Shao Z, Chen Z, Yang J. Effects of mycoplasma pneumoniae infection on sphingolipid metabolism in human lung carcinoma A549 cells. Microb Pathog. 2009;46(2):63–72.CrossRefPubMed
10.
Zurück zum Zitat Wang JR, Zhang H, Yau LF, Mi JN, Lee S, Lee KC, Hu P, Liu L, Jiang ZH. Improved sphingolipidomic approach based on ultra-high performance liquid chromatography and multiple mass spectrometries with application to cellular neurotoxicity. Anal Chem. 2014;86(12):5688–96.CrossRefPubMed Wang JR, Zhang H, Yau LF, Mi JN, Lee S, Lee KC, Hu P, Liu L, Jiang ZH. Improved sphingolipidomic approach based on ultra-high performance liquid chromatography and multiple mass spectrometries with application to cellular neurotoxicity. Anal Chem. 2014;86(12):5688–96.CrossRefPubMed
11.
Zurück zum Zitat Huang H, Tong TT, Yau LF, Chen CY, Mi JN, Wang JR, Jiang ZH. LC-MS based Sphingolipidomic study on A2780 human ovarian Cancer cell line and its Taxol-resistant strain. Sci Rep. 2016;6:34684.CrossRefPubMedPubMedCentral Huang H, Tong TT, Yau LF, Chen CY, Mi JN, Wang JR, Jiang ZH. LC-MS based Sphingolipidomic study on A2780 human ovarian Cancer cell line and its Taxol-resistant strain. Sci Rep. 2016;6:34684.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Ravid T, Tsaba A, Gee P, Rasooly R, Medina EA, Goldkorn T. Ceramide accumulation precedes caspase-3 activation during apoptosis of A549 human lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol. 2003;284(6):L1082–92.CrossRefPubMedPubMedCentral Ravid T, Tsaba A, Gee P, Rasooly R, Medina EA, Goldkorn T. Ceramide accumulation precedes caspase-3 activation during apoptosis of A549 human lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol. 2003;284(6):L1082–92.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, Akiyama T, Shibuya S, Shimeno H. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer. 2003;105(1):1–6.CrossRefPubMed Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, Akiyama T, Shibuya S, Shimeno H. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer. 2003;105(1):1–6.CrossRefPubMed
14.
Zurück zum Zitat Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J. 2006;395(2):311–8.CrossRefPubMedPubMedCentral Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J. 2006;395(2):311–8.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, Hannun YA. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem. 2002;277(15):12587–95.CrossRefPubMed Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, Hannun YA. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem. 2002;277(15):12587–95.CrossRefPubMed
16.
Zurück zum Zitat Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta. 2002;1585(2–3):153–62.CrossRefPubMed Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta. 2002;1585(2–3):153–62.CrossRefPubMed
17.
Zurück zum Zitat Khodadadian M, Leroux ME, Auzenne E, Ghosh SC, Farquhar D, Evans R, Spohn W, Zou Y, Klostergaard J. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro. Lung Cancer. 2009;66(1):48–57.CrossRefPubMed Khodadadian M, Leroux ME, Auzenne E, Ghosh SC, Farquhar D, Evans R, Spohn W, Zou Y, Klostergaard J. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro. Lung Cancer. 2009;66(1):48–57.CrossRefPubMed
18.
Zurück zum Zitat Yang J, Yang C, Zhang S, Mei Z, Shi M, Sun S, Shi L, Wang Z, Wang Y, Li Z, et al. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol Ther. 2015;16(8):1194–204.CrossRefPubMedPubMedCentral Yang J, Yang C, Zhang S, Mei Z, Shi M, Sun S, Shi L, Wang Z, Wang Y, Li Z, et al. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol Ther. 2015;16(8):1194–204.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta. 2008;1781(9):424–34.CrossRefPubMedPubMedCentral Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta. 2008;1781(9):424–34.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Nicholson KM, Quinn DM, Kellett GL, Warr JR. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer. 1999;81(3):423–30.CrossRefPubMedPubMedCentral Nicholson KM, Quinn DM, Kellett GL, Warr JR. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer. 1999;81(3):423–30.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tyler A, Johansson A, Karlsson T, Gudey SK, Brannstrom T, Grankvist K, Behnam-Motlagh P. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. Exp Cell Res. 2015;336(1):23–32.CrossRefPubMed Tyler A, Johansson A, Karlsson T, Gudey SK, Brannstrom T, Grankvist K, Behnam-Motlagh P. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells. Exp Cell Res. 2015;336(1):23–32.CrossRefPubMed
22.
Zurück zum Zitat Kiguchi K, Iwamori Y, Suzuki N, Kobayashi Y, Ishizuka B, Ishiwata I, Kita T, Kikuchi Y, Iwamori M. Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance. Cancer Sci. 2006;97(12):1321–6.CrossRefPubMed Kiguchi K, Iwamori Y, Suzuki N, Kobayashi Y, Ishizuka B, Ishiwata I, Kita T, Kikuchi Y, Iwamori M. Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance. Cancer Sci. 2006;97(12):1321–6.CrossRefPubMed
23.
Zurück zum Zitat Grazide S, Terrisse AD, Lerouge S, Laurent G, Jaffrezou JP. Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines. J Biol Chem. 2004;279(18):18256–61.CrossRefPubMed Grazide S, Terrisse AD, Lerouge S, Laurent G, Jaffrezou JP. Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines. J Biol Chem. 2004;279(18):18256–61.CrossRefPubMed
Metadaten
Titel
LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain
verfasst von
Hao Huang
Tian-Tian Tong
Lee-Fong Yau
Cheng-Yu Chen
Jia-Ning Mi
Jing-Rong Wang
Zhi-Hong Jiang
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2018
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4714-x

Weitere Artikel der Ausgabe 1/2018

BMC Cancer 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.